RT Journal Article
SR Electronic
T1 Cryptic transmission of SARS-CoV-2 in Washington State
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.02.20051417
DO 10.1101/2020.04.02.20051417
A1 Bedford, Trevor
A1 Greninger, Alexander L.
A1 Roychoudhury, Pavitra
A1 Starita, Lea M.
A1 Famulare, Michael
A1 Huang, Meei-Li
A1 Nalla, Arun
A1 Pepper, Gregory
A1 Reinhardt, Adam
A1 Xie, Hong
A1 Shrestha, Lasata
A1 Nguyen, Truong N
A1 Adler, Amanda
A1 Brandstetter, Elisabeth
A1 Cho, Shari
A1 Giroux, Danielle
A1 Han, Peter D.
A1 Fay, Kairsten
A1 Frazar, Chris D.
A1 Ilcisin, Misja
A1 Lacombe, Kirsten
A1 Lee, Jover
A1 Kiavand, Anahita
A1 Richardson, Matthew
A1 Sibley, Thomas R.
A1 Truong, Melissa
A1 Wolf, Caitlin R.
A1 Nickerson, Deborah A.
A1 Rieder, Mark J.
A1 Englund, Janet A.
A1 ,
A1 Hadfield, James
A1 Hodcroft, Emma B.
A1 Huddleston, John
A1 Moncla, Louise H.
A1 Müller, Nicola F.
A1 Neher, Richard A.
A1 Deng, Xianding
A1 Gu, Wei
A1 Federman, Scot
A1 Chiu, Charles
A1 Duchin, Jeff
A1 Gautom, Romesh
A1 Melly, Geoff
A1 Hiatt, Brian
A1 Dykema, Philip
A1 Lindquist, Scott
A1 Queen, Krista
A1 Tao, Ying
A1 Uehara, Anna
A1 Tong, Suxiang
A1 MacCannell, Duncan
A1 Armstrong, Gregory L.
A1 Baird, Geoffrey S.
A1 Chu, Helen Y.
A1 Shendure, Jay
A1 Jerome, Keith R.
YR 2020
UL http://medrxiv.org/content/early/2020/04/16/2020.04.02.20051417.abstract
AB Following its emergence in Wuhan, China, in late November or early December 2019, the SARS-CoV-2 virus has rapidly spread throughout the world. Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections. Here, we analyze 346 SARS-CoV-2 genomes from samples collected between 20 February and 15 March 2020 from infected patients in Washington State, USA. We found that the large majority of SARS-CoV-2 infections sampled during this time frame appeared to have derived from a single introduction event into the state in late January or early February 2020 and subsequent local spread, indicating cryptic spread of COVID-19 before active community surveillance was implemented. We estimate a common ancestor of this outbreak clade as occurring between 18 January and 9 February 2020. From genomic data, we estimate an exponential doubling between 2.4 and 5.1 days. These results highlight the need for large-scale community surveillance for SARS-CoV-2 and the power of pathogen genomics to inform epidemiological understanding.Competing Interest StatementJanet A. Englund is a consultant for Sanofi Pasteur and Meissa Vaccines, Inc., and receives research support from GlaxoSmithKline, AstraZeneca, and Novavax. Helen Chu is a consultant for Merck and GlaxoSmithKline. Jay Shendure is a consultant with Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Nanostring, Phase Genomics, Adaptive Biotechnologies, and Stratos Genomics, and has a research collaboration with Illumina. Michael Famulare, Lea Starita, Pavitra Roychoudhury, Amanda Adler, Peter Han, Kirsten Lacombe, Elisabeth Brandstetter, Caitlin R. Wolf, Richard A Neher, James Hadfield, Nicola F. Müller, Jover Lee, Thomas Sibley, Kairsten Fay, Deborah A. Nickerson, Mark J. Rieder, and Trevor Bedford declare no competing interests.Funding StatementThe Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. The funder was not involved in the design of the study and does not have any ownership over the management and conduct of the study, the data, or the rights to publish. JS is an Investigator of the Howard Hughes Medical Institute. TB is a Pew Biomedical Scholar and is supported by NIH R35 GM119774-01. EBH and RAN are supported by University of Basel core funding. Sequencing analyses of SARS-CoV-2 genomes from California was supported by an NIH grant R33-AI129455 and the Charles and Helen Schwab Foundation to CYC, and an NIH grant K08-CA230156 and the Burroughs-Wellcome CAMS Award to WG. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsensus SARS-CoV-2 genome sequences were deposited into GISAID immediately on generation. They have been submitted to Genbank as well (accession pending). All data used in the paper is also available here: https://github.com/blab/ncov-cryptic-transmission.